ZD6474
information and resources from the National Cancer Institute
NCI Thesaurus | ZD6474
An orally bioavailable 4-anilinoquinazoline. ZD-6474 selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGF2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis. NCI Thesaurus | ZD6474
An orally bioavailable 4-anilinoquinazoline. ZD-6474 selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGF2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis.
|
|
|
|
news articles
Early Data Is Promising in ZD6474 for Hereditary Medullary Thyroid ... Nov 21, 2005
DG News PHILADELPHIA, PA -- November 21, 2005 -- In an early phase 1 trial, ZD6474 is showing positive objective remissions and stabilization of tumours. ...
EU Committee for Orphan Medicinal Products Recommends Orphan Drug ... Dec 14, 2005
news aktuell (Pressemitteilung), ...today that it has received positive opinion from the Committee for Orphan Medicinal Products (COMP) recommending orphan drug designation for ZD6474 (ZACTIMA(TM ...
EU experts back Astra cancer drug "orphan" status Dec 14, 2005
Reuters Zactima, or ZD6474, is also being assessed as a treatment for lung cancer -- a much bigger market -- and final Phase III tests in this indication started last ...
GlaxoSmithKline cancer drug threatens Herceptin market Dec 9, 2005
Nature.com (subscription), ...multitargeted therapies follow close behind in phase 2 trials: Pfizer's Sutent (sunitinib malate), Bayer's Nexavar (sorafenib) and AstraZeneca's ZD6474 (Zactima ...
Early Data Is Promising in ZD6474 for Hereditary Medullary Thyroid ... Nov 21, 2005
DG News PHILADELPHIA, PA -- November 21, 2005 -- In an early phase 1 trial, ZD6474 is showing positive objective remissions and stabilization of tumours. ...
EU Committee for Orphan Medicinal Products Recommends Orphan Drug ... Dec 14, 2005
news aktuell (Pressemitteilung), ...today that it has received positive opinion from the Committee for Orphan Medicinal Products (COMP) recommending orphan drug designation for ZD6474 (ZACTIMA(TM ...
EU experts back Astra cancer drug "orphan" status Dec 14, 2005
Reuters Zactima, or ZD6474, is also being assessed as a treatment for lung cancer -- a much bigger market -- and final Phase III tests in this indication started last ...
GlaxoSmithKline cancer drug threatens Herceptin market Dec 9, 2005
Nature.com (subscription), ...multitargeted therapies follow close behind in phase 2 trials: Pfizer's Sutent (sunitinib malate), Bayer's Nexavar (sorafenib) and AstraZeneca's ZD6474 (Zactima ...
|
|
